Novo Nordisk releases 2025 annual report
Novo Nordisk A/S has issued its annual report for 2025.
Rhea-AI Filing Summary
Novo Nordisk A/S has issued its annual report for 2025. The report is available on the company’s investor website and is also attached in iXBRL format for electronic analysis.
Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Denmark. It focuses on defeating serious chronic diseases, with a heritage in diabetes and efforts to pioneer scientific breakthroughs, expand access to medicines, and work toward prevention and cures.
The company employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares trade on Nasdaq Copenhagen, and its American depositary receipts trade on the New York Stock Exchange under the symbol NVO.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Novo Nordisk (NONOF) announce in this 6-K filing?
Where can investors access Novo Nordisk (NONOF) 2025 annual report?
What kind of company is Novo Nordisk (NONOF)?
How large is Novo Nordisk’s (NONOF) global footprint?
How can investors and media contact Novo Nordisk (NONOF)?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 4, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Novo Nordisk has published its annual report for 2025
Bagsværd, Denmark, 4 February 2026 – Today, Novo Nordisk A/S has issued its 2025 annual report.
The report is available here: https://www.novonordisk.com/investors/annual-report.html and is attached in iXBRL format.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Page 2 of 2
Contacts for further information:
| Novo Nordisk Media: | |
| Ambre James-Brown | Liz Skrbkova (US) |
| +45 3079 9289 | +1 609 917 0632 |
| globalmedia@novonordisk.com | lzsk@novonordisk.com |
| Novo Nordisk Investors: | |
| Michael Novod | Jacob Martin Wiborg Rode |
| +45 3075 6050 | +45 3075 5956 |
| nvno@novonordisk.com | jrde@novonordisk.com |
| Sina Meyer | Max Ung |
| +45 3079 6656 | +45 3077 6414 |
| azey@novonordisk.com | mxun@novonordisk.com |
| Christoffer Sho Togo Tullin | Alex Bruce |
| +45 3079 1471 | +45 3444 2613 |
| cftu@novonordisk.com | axeu@novonordisk.com |
| Frederik Taylor Pitter | |
| +1 609 613 0568 | |
| fptr@novonordisk.com |
Attachments
| · | NOVO-2025-12-31-1-en (https://ml-eu.globenewswire.com/Resource/Download/b3a9153e-1c61-46d4-86c3-18e7aeac204e) |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: |
| Company announcement No 05 / 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 4, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |